These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 22931309)
1. Structure-based drug design for dopamine D3 receptor. Feng Z; Hou T; Li Y Comb Chem High Throughput Screen; 2012 Dec; 15(10):775-91. PubMed ID: 22931309 [TBL] [Abstract][Full Text] [Related]
2. Targeting the dopamine D3 receptor: an overview of drug design strategies. Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands. Cao Y; Min C; Acharya S; Kim KM; Cheon SH Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842 [TBL] [Abstract][Full Text] [Related]
4. Current drug treatments targeting dopamine D3 receptor. Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands. Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029 [TBL] [Abstract][Full Text] [Related]
7. A Molecular Basis for Selective Antagonist Destabilization of Dopamine D Marsango S; Caltabiano G; Jiménez-Rosés M; Millan MJ; Pediani JD; Ward RJ; Milligan G Sci Rep; 2017 May; 7(1):2134. PubMed ID: 28522847 [TBL] [Abstract][Full Text] [Related]
8. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895 [TBL] [Abstract][Full Text] [Related]
9. CoMFA and CoMSIA investigations of dopamine D3 receptor ligands leading to the prediction, synthesis, and evaluation of rigidized FAUC 365 analogues. Salama I; Schlotter K; Utz W; Hübner H; Gmeiner P; Boeckler F Bioorg Med Chem; 2006 Sep; 14(17):5898-912. PubMed ID: 16750374 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833 [TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094 [TBL] [Abstract][Full Text] [Related]
12. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies. Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464 [TBL] [Abstract][Full Text] [Related]
13. Newly Developed Dopamine D Jordan CJ; Humburg BA; Thorndike EB; Shaik AB; Xi ZX; Baumann MH; Newman AH; Schindler CW J Pharmacol Exp Ther; 2019 Dec; 371(3):602-614. PubMed ID: 31562201 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta. Zingales V; Torrisi SA; Leggio GM; Bucolo C; Drago F; Salomone S Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33799860 [TBL] [Abstract][Full Text] [Related]
15. Selectivity and activation of dopamine D3R from molecular dynamics. Feng Z; Hou T; Li Y J Mol Model; 2012 Dec; 18(12):5051-63. PubMed ID: 22752545 [TBL] [Abstract][Full Text] [Related]
16. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. Newman AH; Grundt P; Cyriac G; Deschamps JR; Taylor M; Kumar R; Ho D; Luedtke RR J Med Chem; 2009 Apr; 52(8):2559-70. PubMed ID: 19331412 [TBL] [Abstract][Full Text] [Related]
17. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. Banala AK; Levy BA; Khatri SS; Furman CA; Roof RA; Mishra Y; Griffin SA; Sibley DR; Luedtke RR; Newman AH J Med Chem; 2011 May; 54(10):3581-94. PubMed ID: 21495689 [TBL] [Abstract][Full Text] [Related]
18. Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D Reilly SW; Riad AA; Hsieh CJ; Sahlholm K; Jacome DA; Griffin S; Taylor M; Weng CC; Xu K; Kirschner N; Luedtke RR; Parry C; Malhotra S; Karanicolas J; Mach RH J Med Chem; 2019 May; 62(10):5132-5147. PubMed ID: 31021617 [TBL] [Abstract][Full Text] [Related]
19. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Chien EY; Liu W; Zhao Q; Katritch V; Han GW; Hanson MA; Shi L; Newman AH; Javitch JA; Cherezov V; Stevens RC Science; 2010 Nov; 330(6007):1091-5. PubMed ID: 21097933 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands. Zhou B; Hong KH; Ji M; Cai J Chem Biol Drug Des; 2018 Sep; 92(3):1597-1609. PubMed ID: 29710404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]